Latest news with #MazenDarwazah
Web Release
10-04-2025
- Business
- Web Release
Hikma signs exclusive licensing agreement with pharma& to bring innovative oncology treatment to MENA
By Editor_wr On Apr 10, 2025 Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has announced an exclusive licensing agreement with pharmaand GmbH (pharma&), a global pharmaceutical company based in Vienna, Austria. This agreement grants Hikma exclusive rights to commercialise rucaparib across the Middle East and North Africa (MENA) region. Rucaparib, marketed as Rubraca®, is an innovative small-molecule oral therapy designed to inhibit poly (ADP-ribose) polymerases (PARPs), a family of proteins critical to DNA repair in cancer cells. This mechanism makes rucaparib an important treatment option for patients battling ovarian cancer, the 8th most common cancer in women globally[1], and prostate cancer, the 4th most common cancer worldwide and the second most common cancer in men[2]. Rucaparib has received regulatory approval from both the European Medicines Agency (EMA) and the United States Food and Drug Administration (U.S. FDA). Mazen Darwazah, Hikma's Executive Vice Chairman and President of MENA, said: 'We are pleased to add rucaparib, an innovative oncology treatment, to our growing oncology portfolio in MENA. This agreement is a major step to further enhance patients' access to life-changing treatments and address critical medical needs across the region. By strengthening our oncology portfolio, we reaffirm our commitment to providing advanced cancer treatments and supporting our purpose of putting better health within reach, every day.' As the company's first innovative small-molecule oral therapy in oncology approved by both the U.S. FDA and EMA, this partnership strengthens Hikma's promise of providing better access to life saving treatment options and its commitment to improving patient outcomes. [1] Ovarian cancer statistics | World Cancer Research Fund [2] Prostate cancer statistics | World Cancer Research Fund Comments are closed.
Zawya
10-04-2025
- Business
- Zawya
Jordan: Hikma signs licensing agreement to bring innovative oncology treatment to MENA
AMMAN — Hikma Pharmaceuticals PLC (Hikma) on Wednesday announced an exclusive licensing agreement with pharmaand GmbH (pharma&), a global pharmaceutical company based in Vienna, Austria. The agreement grants Hikma exclusive rights to commercialise rucaparib across the Middle East and North Africa (MENA) region, the Jordan New Agency, Petra, reported. Rucaparib, marketed as Rubraca, is an innovative small-molecule oral therapy designed to inhibit poly (ADP-ribose) polymerases (PARPs), a family of proteins critical to DNA repair in cancer cells. This mechanism makes rucaparib an 'important' treatment option for patients battling ovarian cancer, the eighth most common cancer in women globally, and prostate cancer, the fourth most common cancer worldwide and the second most common cancer in men. Rucaparib has received regulatory approval from the European Medicines Agency (EMA) and the United States Food and Drug Administration (USFDA). Hikma Executive Vice Chairperson and President of MENA Mazen Darwazah said: "We are pleased to add rucaparib, an innovative oncology treatment, to our growing oncology portfolio in MENA.' 'This agreement is a major step to further enhance patients' access to life-changing treatments and address critical medical needs across the region. By strengthening our oncology portfolio, we reaffirm our commitment to providing advanced cancer treatments and supporting our purpose of putting better health within reach, every day,' Darwazah added. As the company's first innovative small-molecule oral therapy in oncology approved by the USFDA and EMA, this partnership boosts Hikma's promise of providing better access to life saving treatment options and its commitment to improving patient outcomes, he noted. © Copyright The Jordan Times. All rights reserved. Provided by SyndiGate Media Inc. (
Jordan Times
09-04-2025
- Business
- Jordan Times
Hikma signs licensing agreement to bring innovative oncology treatment to MENA
Hikma Pharmaceuticals PLC announces an exclusive licensing agreement with pharmaand GmbH to commercialise rucaparib across the Middle East and North Africa (Petra photo) AMMAN — Hikma Pharmaceuticals PLC (Hikma) on Wednesday announced an exclusive licensing agreement with pharmaand GmbH (pharma&), a global pharmaceutical company based in Vienna, Austria. The agreement grants Hikma exclusive rights to commercialise rucaparib across the Middle East and North Africa (MENA) region, the Jordan New Agency, Petra, reported. Rucaparib, marketed as Rubraca, is an innovative small-molecule oral therapy designed to inhibit poly (ADP-ribose) polymerases (PARPs), a family of proteins critical to DNA repair in cancer cells. This mechanism makes rucaparib an 'important' treatment option for patients battling ovarian cancer, the eighth most common cancer in women globally, and prostate cancer, the fourth most common cancer worldwide and the second most common cancer in men. Rucaparib has received regulatory approval from the European Medicines Agency (EMA) and the United States Food and Drug Administration (USFDA). Hikma Executive Vice Chairperson and President of MENA Mazen Darwazah said: "We are pleased to add rucaparib, an innovative oncology treatment, to our growing oncology portfolio in MENA.' 'This agreement is a major step to further enhance patients' access to life-changing treatments and address critical medical needs across the region. By strengthening our oncology portfolio, we reaffirm our commitment to providing advanced cancer treatments and supporting our purpose of putting better health within reach, every day,' Darwazah added. As the company's first innovative small-molecule oral therapy in oncology approved by the USFDA and EMA, this partnership boosts Hikma's promise of providing better access to life saving treatment options and its commitment to improving patient outcomes, he noted.
Zawya
09-04-2025
- Business
- Zawya
Hikma signs exclusive licensing agreement with pharma& to bring innovative oncology treatment to MENA
Amman – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has announced an exclusive licensing agreement with pharmaand GmbH (pharma&), a global pharmaceutical company based in Vienna, Austria. This agreement grants Hikma exclusive rights to commercialise rucaparib across the Middle East and North Africa (MENA) region. Rucaparib, marketed as Rubraca®, is an innovative small-molecule oral therapy designed to inhibit poly (ADP-ribose) polymerases (PARPs), a family of proteins critical to DNA repair in cancer cells. This mechanism makes rucaparib an important treatment option for patients battling ovarian cancer, the 8th most common cancer in women globally [1], and prostate cancer, the 4th most common cancer worldwide and the second most common cancer in men [2]. Rucaparib has received regulatory approval from both the European Medicines Agency (EMA) and the United States Food and Drug Administration (U.S. FDA). Mazen Darwazah, Hikma's Executive Vice Chairman and President of MENA, said: 'We are pleased to add rucaparib, an innovative oncology treatment, to our growing oncology portfolio in MENA. This agreement is a major step to further enhance patients' access to life-changing treatments and address critical medical needs across the region. By strengthening our oncology portfolio, we reaffirm our commitment to providing advanced cancer treatments and supporting our purpose of putting better health within reach, every day.' As the company's first innovative small-molecule oral therapy in oncology approved by both the U.S. FDA and EMA, this partnership strengthens Hikma's promise of providing better access to life saving treatment options and its commitment to improving patient outcomes. For inquiries: Zaina AlAtiyat Manager, MENA Communications & Corporate Affairs ZAlAtiyat@ About Hikma Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the MENA and Europe. For more information, please visit: [1] Ovarian cancer statistics | World Cancer Research Fund [2] Prostate cancer statistics | World Cancer Research Fund
Mid East Info
31-01-2025
- Business
- Mid East Info
M42 and Hikma sign strategic MOU to enhance preventive and predictive cancer care in the UAE - Middle East Business News and Information
M42, a global health leader powered by artificial intelligence (AI), and Hikma Pharmaceuticals PLC (Hikma), announced the signing of a strategic memorandum of understanding (MOU), to accelerate the implementation of more precise, preventive and predictive cancer care programmes, utilising cutting-edge genomics screening technology. Under this agreement, Hikma and M42 will enhance their collaboration to promote the use of Shield™, a non-invasive laboratory-developed test (LDT) by Guardant Health Inc., for colorectal cancer (CRC) screening, aiming to improve screening adherence rates in the UAE. Shield™ is the first blood test to be approved by the US FDA as a primary screening option for CRC, meaning healthcare providers can offer Shield in a manner similar to all other non-invasive methods recommended in screening guidelines. Dr. Fahed Al Marzooqi, Chief Executive Officer, Integrated Health Solutions, M42, said: 'At M42, we are committed to harnessing cutting-edge technologies to improve patient outcomes and empower health systems to deliver proactive care. This collaboration with Hikma reflects our dedication to supporting Abu Dhabi's broader efforts to lead in next-generation screening and health innovation. By integrating AI and genomics-driven solutions, we are redefining traditional healthcare models to create a healthier, more sustainable future for all.' Mazen Darwazah, Hikma's Executive Vice Chairman and President of MENA, said: ' We are proud to sign this strategic partnership with M42 – a company that shares our commitment to innovation shaping the future of healthcare to improve patient outcomes. This important endeavour is focused on enhancing early disease detection, enabling more precise diagnoses, and facilitating more effective treatments, particularly in oncology and preventive care, which is aligned with our ambition of providing broader healthcare solutions focused on precision medicine.' Last year Hikma announced that it had signed an exclusive agreement with Guardant Health, Inc. for the commercialisation and marketing of Guardant Health's portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumour mutation profiling across all solid cancers in the Middle East and North Africa (MENA). The agreement includes tests such as the US FDA approved Shield™ for colorectal cancer screening and early detection, as well as Guardant Reveal™ for minimal residual disease detection and recurrence monitoring and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers. The introduction of the Shield™ test for colorectal cancer screening marks a transformative step in advancing precision and preventive healthcare across the region.
